Medigene (DE:MDG1) just unveiled an update.

Medigene AG has announced a significant financial update, revealing a loss of more than half of its share capital, necessitating an Extraordinary General Meeting to formally report this to shareholders. Additionally, the company has adjusted its cash runway, moving it from July 2025 to May 2025, due to unmet milestone payments and income from contractual obligations. Despite these challenges, Medigene remains committed to maintaining its 2024 financial guidance for R&D expenses and revenues, and is actively seeking additional financing to sustain operations.

More about Medigene
Medigene AG is a biotechnology company based in Planegg/Martinsried, Germany. It focuses on the development of innovative immunotherapies for the treatment of cancer, leveraging its expertise in T cell receptor (TCR) technology.

YTD Price Performance: 50.40%
Average Trading Volume: 583
Technical Sentiment Signal: Buy
Current Market Cap: €23.43M

For an in-depth examination of MDG1 stock, go to TipRanks’ Stock Analysis page.

Medigene AG Reports Significant Share Capital Loss and Cash Runway Adjustment

Medigene AG, a biotechnology company based in Planegg/Martinsried, Germany, has announced a significant financial update. The company reported a loss of more than half of its share capital, necessitating an Extraordinary General Meeting to formally report this to shareholders. Additionally, the company has adjusted its cash runway, moving it from July 2025 to May 2025, due to unmet milestone payments and income from contractual obligations. Despite these challenges, Medigene remains committed to maintaining its 2024 financial guidance for R&D expenses and revenues, and is actively seeking additional financing to sustain operations.